TrialAmerican journal of clinical dermatology2018

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.

Caitriona Ryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.